Homework Help is Here – Start Your Trial Now!
Math
Probability
Subjects with preexisting cardiovascular symptoms who were receiving subutramine, an appetite suppressant, were found to be at increased risk of cardiovascular events while taking the drug. The study included 9645 overweight or obese subjects with preexisting cardiovascular disease and/or type 2 diabetes. The subjects were randomly assigned to subutramine (4798 subjects) or a placebo (4847 subjects) in a double-blind fashion. The primary outcome measured was the occurrence of any of the following events: nonfatal myocardial infarction or stroke, resuscitation after cardiac arrest, or cardiovascular death. The primary outcome was observed in 552 subjects in the subutramine group and 491 subjects in the placebo group. Do the data give good reason to think that there is a difference between the proportions of treatment and placebo subjects who experienced the primary outcome? (Note that sibutramine has not been available in the United States since the end of 2010 due to its manufacturer's concerns over increased risk of heart attack or stroke, although at the present time, it can still be purchased in other countries.)

Subjects with preexisting cardiovascular symptoms who were receiving subutramine, an appetite suppressant, were found to be at increased risk of cardiovascular events while taking the drug. The study included 9645 overweight or obese subjects with preexisting cardiovascular disease and/or type 2 diabetes. The subjects were randomly assigned to subutramine (4798 subjects) or a placebo (4847 subjects) in a double-blind fashion. The primary outcome measured was the occurrence of any of the following events: nonfatal myocardial infarction or stroke, resuscitation after cardiac arrest, or cardiovascular death. The primary outcome was observed in 552 subjects in the subutramine group and 491 subjects in the placebo group. Do the data give good reason to think that there is a difference between the proportions of treatment and placebo subjects who experienced the primary outcome? (Note that sibutramine has not been available in the United States since the end of 2010 due to its manufacturer's concerns over increased risk of heart attack or stroke, although at the present time, it can still be purchased in other countries.)

A First Course in Probability (10th Edition)
A First Course in Probability (10th Edition)
10th Edition
ISBN:9780134753119
Author:Sheldon Ross
Publisher:Sheldon Ross
Chapter1: Combinatorial Analysis
Section: Chapter Questions
Problem 1.1P: a. How many different 7-place license plates are possible if the first 2 places are for letters and...
See similar textbooks
icon
Related questions
Question

Help on this question

Subjects with preexisting cardiovascular symptoms who were receiving subutramine, an appetite suppressant, were found to be at increased risk of cardiovascular events while taking the drug. The study included 9645 overweight or obese subjects with preexisting cardiovascular disease and/or type 2 diabetes. The subjects were randomly assigned to subutramine (4798 subjects) or a placebo (4847 subjects) in a double-blind fashion. The primary outcome measured was the occurrence of any of the following events: nonfatal myocardial infarction or stroke, resuscitation after cardiac arrest, or cardiovascular death. The primary outcome was observed in 552 subjects in the subutramine group and 491 subjects in the placebo group. Do the data give good reason to think that there is a difference between the proportions of treatment and placebo subjects who experienced the primary outcome? (Note that sibutramine has not been available in the United States since the end of 2010 due to its manufacturer's concerns over increased risk of heart attack or stroke, although at the present time, it can still be purchased in other countries.) Source adapted from W. P. T. James et al., "Effect of Sibutramine on cardiovascular outcomes in overweight and obese subjects," New England Journal of Medicine, 363 (2010), pp. 905-917.
Transcribed Image Text:Subjects with preexisting cardiovascular symptoms who were receiving subutramine, an appetite suppressant, were found to be at increased risk of cardiovascular events while taking the drug. The study included 9645 overweight or obese subjects with preexisting cardiovascular disease and/or type 2 diabetes. The subjects were randomly assigned to subutramine (4798 subjects) or a placebo (4847 subjects) in a double-blind fashion. The primary outcome measured was the occurrence of any of the following events: nonfatal myocardial infarction or stroke, resuscitation after cardiac arrest, or cardiovascular death. The primary outcome was observed in 552 subjects in the subutramine group and 491 subjects in the placebo group. Do the data give good reason to think that there is a difference between the proportions of treatment and placebo subjects who experienced the primary outcome? (Note that sibutramine has not been available in the United States since the end of 2010 due to its manufacturer's concerns over increased risk of heart attack or stroke, although at the present time, it can still be purchased in other countries.) Source adapted from W. P. T. James et al., "Effect of Sibutramine on cardiovascular outcomes in overweight and obese subjects," New England Journal of Medicine, 363 (2010), pp. 905-917.
O Macmillan N || 0.002 Incorrect Use either software or the bottom row of Table C for the P-value. Give your answer to four decimal places. P-value: 0.0266 Incorrect
Transcribed Image Text:O Macmillan N || 0.002 Incorrect Use either software or the bottom row of Table C for the P-value. Give your answer to four decimal places. P-value: 0.0266 Incorrect
Expert Solution
steps

Step by step

Solved in 2 steps with 1 images

SEE SOLUTIONCheck out a sample Q&A here
Blurred answer